Leerink Partnrs Has Positive Outlook of Hologic Q4 Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Analysts at Leerink Partnrs upped their Q4 2025 earnings estimates for shares of Hologic in a research note issued on Thursday, February 6th. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will post earnings of $1.13 per share for the quarter, up from their previous forecast of $1.12. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Hologic's current full-year earnings is $4.27 per share.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%.

Other equities research analysts also recently issued research reports about the company. Evercore ISI decreased their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a report on Thursday, February 6th. Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price for the company. in a report on Monday, February 3rd. Royal Bank of Canada decreased their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. Raymond James reaffirmed an "outperform" rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Morgan Stanley decreased their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Hologic has an average rating of "Moderate Buy" and a consensus target price of $85.77.

Hologic Stock Performance

Shares of NASDAQ HOLX traded up $0.09 during mid-day trading on Monday, hitting $63.62. The stock had a trading volume of 1,940,048 shares, compared to its average volume of 2,545,433. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49. The company has a 50 day moving average of $71.28 and a two-hundred day moving average of $77.37. The firm has a market cap of $14.36 billion, a PE ratio of 20.07, a PEG ratio of 2.14 and a beta of 0.97. Hologic has a twelve month low of $63.39 and a twelve month high of $84.67.

Institutional Trading of Hologic

A number of hedge funds and other institutional investors have recently modified their holdings of HOLX. State Street Corp increased its position in shares of Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock valued at $847,944,000 after acquiring an additional 81,057 shares during the last quarter. Geode Capital Management LLC raised its position in Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock valued at $412,159,000 after purchasing an additional 144,838 shares during the period. FMR LLC lifted its stake in Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after purchasing an additional 24,358 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock valued at $322,272,000 after buying an additional 129,035 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is currently owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.